Bloom Science, Inc. announced the appointment of Dr. Grace E. Colon as Chair of its Board of Directors, effectively 18 May 2023. A distinguished scientist and leading executive in biotechnology, Dr. Colon will lend her business, scientific, clinical and operational expertise towards helping Bloom Science in a research and development of new diagnostics and transformative medicines for patients with complex neurological disorders. Dr. Colon has over 25 years of experience in biopharma, genomics, diagnostics, healthcare, industrial microbiology/biotechnology, synthetic biology, venture capital, management consulting, and entrepreneurship.

Most recently, she was CEO and President of InCarda Therapeutics from 2013 to 2022, where she led the company from a seed stage start-up to one with a best-in-class inhaled cardiovascular disease therapy being evaluated in a pivotal Phase 3 trial and a growing pipeline. She serves on the boards of CareDx, Voyager Therapeutics, the MIT Corporation (MIT's Board of Trustees) and the Biotechnology Innovation Organization (BIO), and is also Executive Chair (formerly CEO) of ProterixBio. Formerly, Dr. Colon held senior executive roles at Intrexon Corporation, Gilead Sciences, and Affymetrix.

She was a partner at New Science Ventures, a New York based venture capital firm, and served on the boards of Paradigm Diagnostics (acquired by Exact Sciences), PerceptiMed and Cocoon Biotech and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University. Earlier in her career, Dr. Colon was a management consultant at McKinsey Company and an engineer at Merck. She received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was a National Science Foundation Fellow.

She also holds an undergraduate degree in chemical engineering from the University of Pennsylvania.